{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:51:18Z","timestamp":1793962278312,"version":"4.8.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The objective of this study was to explore differences in outcomes between first-line rituximab plus bendamustine (R-B) and R-CHOP\/R-DHAP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, dexamethasone, cytarabine, cisplatin) in transplant-eligible patients with mantle cell lymphoma (MCL). A population-based cohort of 97 patients aged 18 to 65 years with stage II-IV MCL, consecutively treated with R-B was retrospectively identified at BC Cancer. Baseline characteristics, response rates, and outcomes were compared with the cohort of 232 patients with MCL randomized to the R-CHOP\/R-DHAP arm of the MCL Younger trial. The primary endpoint was the hazard ratio (HR) of the progression-free survival (PFS) comparison between both groups, adjusted for MCL International Prognostic Index (MIPI), Ki67 index, and blastoid\/ pleomorphic morphology. Ann Arbor stage, lactate dehydrogenase, MIPI, blastoid morphology, and MCL35 assignments were similar between both groups. The overall response rate (ORR) to R-B was 90% (54% complete response [CR]); 77% of patients proceeded to autologous stem cell transplantation (ASCT) and 78% received maintenance rituximab (MR). The ORR to R-CHOP\/R-DHAP was 94% (54% CR); 78% proceeded to ASCT and 2% received MR. There were no differences in PFS in unadjusted (HR, 0.87; 95% confidence interval [CI], 0.53-1.41; P = .56) or adjusted (HR, 0.79; 95% CI, 0.45-1.37; P = .40) comparisons. There were no clear differences in secondary endpoints in unadjusted or adjusted analyses. This retrospective adjusted comparison of 2 independent cohorts of younger patients with MCL suggests that R-B with ASCT and maintenance rituximab is a feasible and effective first-line treatment, with outcomes comparable to R-CHOP\/R-DHAP with ASCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007371","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T18:02:44Z","timestamp":1650391364000},"page":"5285-5294","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"first","affiliation":[{"name":"1BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-1389","authenticated-orcid":false,"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[{"name":"2Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"3H\u00f4pital Necker, Assistance Publique H\u00f4pitaux de Paris, University of Paris Descartes, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Hematopathology Section, University-Hospital Schleswig-Holstein, University of Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Szymczyk","sequence":"additional","affiliation":[{"name":"5Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Bosly","sequence":"additional","affiliation":[{"name":"6Centre Hospitalier Universitaire \u2013 Universit\u00e9 Catholique de Louvain Mont-Godinne-Dinant, Yvoir, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Unterhalt","sequence":"additional","affiliation":[{"name":"7Medizinische Klinik III, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"8Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen A.","family":"Ramsower","sequence":"additional","affiliation":[{"name":"8Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"9H. Lee Moffitt Cancer Centre & Research Institute and Morsani College of Medicine, University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"1BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"1BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"1BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"1BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-5249","authenticated-orcid":false,"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"7Medizinische Klinik III, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"2022091915284053400_B1","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol."},{"issue":"10044","key":"2022091915284053400_B2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet."},{"key":"2022091915284053400_B3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2021-150181","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a long-term follow-up of the randomized, open-label, phase 3 trial of the european mantle cell lymphoma Network [abstract]","volume":"138","author":"Hermine","year":"2021","journal-title":"Blood."},{"issue":"13","key":"2022091915284053400_B4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med."},{"issue":"16","key":"2022091915284053400_B5","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood."},{"issue":"9873","key":"2022091915284053400_B6","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet."},{"issue":"12","key":"2022091915284053400_B7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol."},{"issue":"15","key":"2022091915284053400_B8","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1182\/bloodadvances.2020002068","article-title":"Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma","volume":"4","author":"Villa","year":"2020","journal-title":"Blood Adv."},{"issue":"20","key":"2022091915284053400_B9","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/bloodadvances.2019000526","article-title":"Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma","volume":"3","author":"Kamdar","year":"2019","journal-title":"Blood Adv."},{"issue":"10","key":"2022091915284053400_B10","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/annonc\/mdx333","article-title":"Observation as the initial management strategy in patients with mantle cell lymphoma","volume":"28","author":"Abrisqueta","year":"2017","journal-title":"Ann Oncol."},{"issue":"4","key":"2022091915284053400_B11","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022091915284053400_B12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12308-020-00418-4","article-title":"Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma","volume":"13","author":"Ramsower","year":"2020","journal-title":"J Hematop."},{"issue":"4","key":"2022091915284053400_B13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/bjh.15519","article-title":"Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network","volume":"184","author":"Rauert-Wunderlich","year":"2019","journal-title":"Br J Haematol."},{"key":"2022091915284053400_B14","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1182\/blood-2021-151275","article-title":"Clinical validation of MCL35 in mantle cell lymphoma patients \u226565 years receiving bendamustine-rituximab [abstract]","volume":"138","author":"Rosenthal","year":"2021","journal-title":"Blood."},{"issue":"15","key":"2022091915284053400_B15","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022091915284053400_B16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol."},{"issue":"19","key":"2022091915284053400_B17","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood."},{"key":"2022091915284053400_B18","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","article-title":"Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial)","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol."},{"key":"2022091915284053400_B19","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2021.39.15_suppl.7504","article-title":"Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice","volume":"39","author":"Martin","year":"2021","journal-title":"J Clin Oncol."},{"key":"2022091915284053400_B20","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood-2019-129404","article-title":"Maintenance rituximab improves outcomes in mantle cell lymphoma patients who respond to induction therapy with bendamustine + rituximab without autologous transplant [abstract]","volume":"134","author":"Hill","year":"2019","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/18\/5285\/1920293\/advancesadv2022007371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/18\/5285\/1920293\/advancesadv2022007371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T15:29:16Z","timestamp":1663601356000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/18\/5285\/484992\/Bendamustine-or-high-dose-cytarabine-based"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":20,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,9,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007371","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}